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Abstract
Introduction: With the aim of searching genetic factors associated with the response to an immune treatment based on
autologous monocyte-derived dendritic cells pulsed with autologous inactivated HIV, we performed exome analysis by screening
more than 240,000 putative functional exonic variants in 18 HIV-positive Brazilian patients that underwent the immune
treatment.
Methods: Exome analysis has been performed using the ILLUMINA Infinium HumanExome BeadChip. zCall algorithm allowed
us to recall rare variants. Quality control and SNP-centred analysis were done with GenABEL R package. An in-house imple-
mentation of the Wang method permitted gene-centred analysis.
Results: CCR4-NOT transcription complex, subunit 1 (CNOT1) gene (16q21), showed the strongest association with the modi-
fication of the response to the therapeutic vaccine (p0.00075). CNOT1 SNP rs7188697 A/G was significantly associated with
DC treatment response. The presence of a G allele indicated poor response to the therapeutic vaccine (p0.0031; OR33.00;
CI1.74624.66), and the SNP behaved in a dominant model (A/A vs. A/GG/G p0.0009; OR107.66; 95% CI3.85
3013.31), being the A/G genotype present only in weak/transient responders, conferring susceptibility to poor response to the
immune treatment.
Discussion: CNOT1 is known to be involved in the control of mRNA deadenylation and mRNA decay. Moreover, CNOT1 has been
recently described as being involved in the regulation of inflammatory processes mediated by tristetraprolin (TTP). The TTP-
CCR4-NOT complex (CNOT1 in the CCR4-NOT complex is the binding site for TTP) has been reported as interfering with HIV
replication, through post-transcriptional control. Therefore, we can hypothesize that genetic variation occurring in the CNOT1
gene could impair the TTP-CCR4-NOT complex, thus interfering with HIV replication and/or host immune response.
Conclusions: Being aware that our findings are exclusive to the 18 patients studied with a need for replication, and that the
genetic variant of CNOT1 gene, localized at intron 3, has no known functional effect, we propose a novel potential candidate
locus for the modulation of the response to the immune treatment, and open a discussion on the necessity to consider the host
genome as another potential variant to be evaluated when designing an immune therapy study.
Keywords: DC immunotherapy; HIV; exome analysis; CNOT1; TTP.
Received 30 October 2013; Accepted 27 November 2013; Published 10 January 2014
Copyright:– 2014 Moura R et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution
3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Introduction
Dendritic cell (DC)-based immunotherapy appeared to be an
interesting strategy to fight HIV-1 infection and has been
proposed firstly as an alternative treatment for HIV-positive
(HIV) patients, then as a co-adjuvant treatment for com-
bined antiretroviral therapy (cART). Indeed, it represents a
great chance to investigate the host immune response against
the virus. At this time, 11 clinical trials (http://clinicaltrials.
gov/) had been concluded and seven are still ongoing [1,2].
The design of these clinical trials, in terms of antigens used to
pulse DC (inactivated whole virus, viral peptides, mRNA,
recombinant virus vectors, etc.), DC preparation and dosage,
varies between different research groups [13]. All DC
treatments resulted in being safe and well-tolerated. How-
ever, only a few trials showed some results in terms of viral
replication control. In particular, the trials conducted by Lu
et al. [3] and Garcia et al. [2], implying a similar approach,
even if the first enrolled patients without cART treatment
while the second considered HIV patients who stopped their
cART treatment, appeared to be able to partially control
plasma viral load (PVL) for up to 12 or six months, respectively.
These findings are the most promising at the moment, but it is
interesting to note that only a fraction of patients were able to
positively respond to the DC-based treatment.
In the review of Garcia et al. [1], all variables concern-
ing the distinct steps of the immune therapy preparation,
Moura R et al. Journal of the International AIDS Society 2014, 17:18938
http://www.jiasociety.org/index.php/jias/article/view/18938 | http://dx.doi.org/10.7448/IAS.17.1.18938
1
clinical trial design and immunological monitoring of treated
patients have been deeply considered, proving interesting
findings useful for unification criteria of future therapeutic
vaccine studies. However, within all the variables considered,
the host genome and its influence on the response to
therapeutic vaccines have never been taken into account,
even if it is well known to affect both HIV-1 replication and
AIDS progression [4].
Our research group in 2010 published an article reporting
the analysis of innate immunity genome (149 genes and
768 SNPs screened) in the 18 HIV patients from the Lu
et al. clinical trial [3]. Two SNPs, in MBL2 and NOS1 genes,
have been associated with better and worse responses to
the immune therapy, respectively [5]. In our retrospective
analysis, although limited to the innate immunity genome,
we evidenced the importance of the host genome as a vari-
able to be considered in the design of a therapeutic vaccine
study. Now we are reporting our findings related to the
analysis of more than 240,000 exonic variants on the same 18
HIV patients, in search for other genetic factors potentially
associated with the response to an immune therapy based
on autologous monocyte-derived DCs pulsed with autologous
inactivated HIV.
Methods
Patient’s classification
The 18 HIV patients who underwent the DC-based treat-
ment were classified as Good Responders (GR) and Weak or
Transient Responders (WTR). GR were those who had 90% of
PVL reduction after the treatment, as reported in the original
study of Lu et al. [3].
Exome analysis
Genomic DNAs of 18 HIV patients from the study of Lu
et al. [3] were already available and their quality/quantity
was checked at our laboratory. Exome analysis has been
performed using the ILLUMINA Infinium Human Exome Bead
Chip following manufacturer’s protocols. The exonic content
consists of more than 240,000 markers with minimum allele
frequency0.05 (mostly cSNPs or few intronic variants
known to have been previously associated with clinical
phenotypes), representing diverse populations including
European, African, Chinese, and Hispanic individuals.
Data quality control and statistical analysis
Since ILLUMINA exome array has many rare variants, the
GenCall (the default ILLUMINA algorithm for genotype call-
ing) could exclude some of them. For this reason, we used
the zCall algorithm [6] specifically tailored for rare variants.
The quality control (QC) for the recalling process was
performed through the GenABEL [7] package, with a call-rate
cut-off set at 99% per SNP call-rate per individual, along with
a 95% threshold for identity by state (IBS) and a cut-off of
0.2 for the false discovery rate applied to HardyWeinberg
equilibrium (HWE) tests. After the QC procedures, 43,636
SNPs (relating to 7,572 genes) passed in all criteria and no
individuals were excluded due to low call-rates or any other
parameter.
We performed both SNP-centred (also through the
GenABEL package) and gene-centred analyses with genomic
correction [8]. For gene-based analysis, we used an in-house
implementation of the method proposed by Wang & Abbott
2008 [9]. Given the small number of samples in the dataset,
p values were obtained empirically through a permutation
process.
Results and discussion
The SNP-based approach did not reveal any significant
association between the exonic markers and HIV immuno-
treatment response. Being aware of the limited power of
the experiment to detect one single variant association, we
performed a gene-based analysis that considered all variants
linked as one single piece of information, thus increasing the
power of the test. An excerpt of 10 results of gene-centred
analysis is reported in Table 1 (the complete results of both
SNP and gene-centred tests are available at http://goo.gl/
Vb8suZ link).
Gene-centred analysis showed that CNTO1 was the most
significantly associated with the response to the immune
vaccine. After genetic evaluation we performed a Panther
http://www.pantherdb.org/) analysis on the top 10 genes
shown in Table 1 in order to investigate if their biological
functions were possibly involved in the control of HIV-1
replication.
Within the 10 genes, we selected CNOT1 because the
Panther-based research evidenced a possible involvement in
the control of viral replication. CNOT1 codifies for the core
subunit of the CCR4NOT deanylase complex, which is
involved in the control of gene expression through transcrip-
tional regulation and mRNA decay [10,11]. In our opinion, an
altered post-transcriptional process may affect both virion
production and host-cell response, as discussed further on.
Within the 19 SNPs distributed in CNOT1 gene represented
in the ILLUMINA Exome Chip, 15 had fixed monomorphic
alleles in our sample while four were polymorphic. Only one
SNP, namely the rs7188697 (AG transition) out of four,
showed significant association with DC treatment response.
Table 2 reports the different distribution of allele and
Table 1. Results from gene-centred analysis. The genes are
listed by the related p value just for illustrative purposes
Gene symbol Full name Chr p
CNOT1 CCR4-NOT transcription complex,
subunit 1
16 0.000026
CNTN4 Contactin 4 3 0.000110
N4BP2L2 NEDD4 binding protein 2-like 2 13 0.000350
MANEA Mannosidase, endo-alpha 6 0.000410
OR4E2 Olfactory receptor, family 4,
subfamily E, member 2
14 0.000550
NHSL1 NHS-like 1 6 0.000580
MTA1 Metastasis associated 1 14 0.001000
FAIM Fas apoptotic inhibitory molecule 3 0.001100
FGFR2 Fibroblast growth factor
receptor 2
10 0.001420
ZNF292 Zinc finger protein 292 6 0.001650
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genotype frequencies of rs7188697 CNOT1 SNP in GR and
WTR patients. The presence of the G allele was strongly
associated with poor response to the immune treatment
(p0.0031; OR33.00; 95% CI1.74624.66). This was
consistent with a dominant model, i.e. A/A vs. A/GGG
(OR107.66; 95% CI3.853013.31; p0.0009), being the
A/G or G/G genotypes present only in WTR patients, con-
ferring high susceptibility to a poor response to the treat-
ment. On the other hand, the A/A genotype, present only
in GR subjects, was associated with good response to the
immune treatment, as visible in Figure 1.
Furthermore, we evaluated if there was any influence of
CNOT1 genotypes on PVL reported in the work of Lu et al. [3],
using the Mann-Whitney test with GraphPad Prism software.
For this test, a pB0.05 was considered statistically signifi-
cant. The CNOT1 rs7188697 genotypes also correlated with
PVL changes in the 18 HIV patients, since only individuals
with A/A genotype showed significant reduction of PVL.
After genetic analysis, we also performed an in silico
evaluation of the possible interactions between the pro-
teins encoded by the 10 selected genes (see Table 1) using
the GeneMania Software (http://www.genemania.org/). We
searched for possible boundaries prediction between CNOT1
and the proteins encoded by the other nine genes, with-
out finding any common pathway or predicted interaction
between them.
When considering the role of CNOT1 in the process of HIV-
1 replication, this protein appeared to be important both in
immune response as well as in HIV-1 replication. Paul et al.
[12] suggested that CNOT1 is involved in the transcriptional
regulation of the major histocompatibility complex (MHC)
class II transactivator (CIITA) and MHC-II expression linking
CNOT1 with antigen presentation. Moreover, CNOT1 has
been recently described to interact with tristetraprolin (TTP),
an RNA-binding protein able to regulate and control the
inflammatory response with a mechanism involving the
reduction of the expression profile of several inflammatory
cytokines [13].
Conversely, TTP was reported to be able to inhibit HIV-1
replication by directly binding viral genome interfering with
RNA post-transcriptional mechanisms [14].
Table 2. Alleles and genotypes counts and frequencies of rs7188697 polymorphism of CNOT1 gene were reported for the 18 HIV
patients of the DC-based immune treatment carried out by Lu et al. [3], classified as Weak or Transient Responders (WTR) and Good
Responders (GR). Odds ratio (OR), 95% confidence intervals (95% CI) and p values from the Chi-squared test for the association
between the rs7188697 SNP and the response to the immune treatment. Results for different genetic models are shown
CNOT1 SNP (rs7188697)
Weak or Transient
Responders (WTR) (n10)
Good Responders
(GR) (n8) OR (95% CI) p
Alleles
A 10 (0.5) 16 (1) Reference
G 10 (0.5) 0 (0) 33.00 (1.74624.66) 0.0031
Genotypes and models
Codominant
A/A 1 (0.1) 8 (1) Reference 0.0007
A/G 8 (0.8) 0 (0) 96.33 (3.422715.42) 0.0015
G/G 1 (0.1) 0 (0) 17.00 (0.46648.24) 0.4292
Dominant
A/A 1 (0.1) 8 (1) Reference
A/GG/G 9 (0.9) 0 (0) 107.66 (3.853013.31) 0.0009
Recessive
A/AA/G 9 (0.9) 8 (1) Reference
G/G 1 (0.1) 0 (0) 2.68 (0.0975.12) 0.9084
Overdominant
A/AG/G 2 (0.2) 8 (1) Reference
A/G 8 (0.8) 0 (0) 57.80 (2.391392.38) 0.0035
The bold values indicate the genetic model to be considered.
Figure 1. Correlation between CNOT1 rs7188697 genotypes with
PVL changes in the 18 HIV patients who have undergone the
immune treatment.
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With all of this considered, we might hypothesize that
CNOT1 could affect immune response against HIV-1 indirectly
through the transcriptional control of MHC-II and inflamma-
tory genes, and possibly directly interact with TTP in the
inhibition of virus replication. In this way, genetic variation
occurring in the CNOT1 gene, identified as a potential can-
didate for poor response to the therapeutic vaccine, could
impair the TTP-CCR4-NOT complex, thus interfering with
mRNA stability of HIV-1 RNA and inflammatory transcripts,
promoting an increased production of viral particles and
inflammatory status, both important factors of poor prog-
nosis of HIV-1 infection. Moreover, high HIV-1 replication
rates and chronic inflammation have been described as
potentially affecting HIV DCs manipulation and anti-HIV
therapeutic vaccine response [1518].
Figure 2 establishes a mechanism on how CNOT1 would
be involved in the control of viral replication and immune
response.
The rs7188697 CNOT1 SNP, associated with WTR, is
localized at intron 3 of the gene and, to our knowledge,
has no functional implication in the regulation of CNOT1
expression. For this reason, we are cautious in the inter-
pretation of our findings and aware that no study until now
has aimed at disclosing a possible association of CNOT1
genetic variations and susceptibility to HIV infection or virus
replication.
With the aim of disclosing if rs7188697 CNOT1 SNP could
be a potential genetic marker, we investigated the distribu-
tion of its allele frequencies in the ethnic groups described in
NCBI SNPs database (http://www.ncbi.nlm.nih.gov/projects/
SNP/snp_ref.cgi?rs7188697): the G allele, strongly asso-
ciated with poor response to the immune treatment, is well
represented and distributed in the HapMap-CEU (European,
A0.691; G0.309), HapMap-HCB (Asian Chinese, A0.
464; G0.536), HapMap-JPT (Asian-Japanese A0.663;
G0.338) and HapMap-YRI (Sub-Saharan African A0.840;
G0.160) populations. Being quite frequent with a minimum
allele frequency (MAF) 16% (YRI) in all of the HapMap
populations screened, we can consider rs7188697 SNP as a
well-represented and potential genetic marker.
Since our study is retrospective and only genomic DNA
from the 18 HIV patients of Lu et al. [3] was available, we
Possible effect of CNOT1 SNPs on HIV-1 biology Possible effect of CNOT1 SNPs on immune response
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Figure 2. Hypothesis for CNOT1 involvement in anti-HIV DC-based immune treatment response. (a) CNOT1 could interact with TTP leading
to the repression of HIV transcripts. (b) SNPs in CNOT1 could affect TTP and/or mRNA binding augmenting HIV RNA stability and the
consequent production of HIV virions. (c) CNOT1 could, directly or interacting with TTP, inhibit the expression of immune genes (such as
cytokines and MHC-II) and consequently the immune response. (d) SNPs in CNOT1 could affect mRNA binding augmenting mRNA stability
and the consequent expression of immune genes, leading to an increased immune response.
CNOT1: CCR4-NOT complex; TTP: tristetraprolin; SNPs: single nucleotide polymorphisms. increase; ¡decrease.
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were not able to perform any functional study (i.e. evalua-
tion of CNOT1 gene expression) to confirm our hypothesis.
Moreover, our findings have been obtained just on patients
from a single phase I trial such as the one of Lu et al. [3], so
they should be considered as ‘‘exclusive to the study’’ and
strongly need to be replicated in other DC vaccine patients
from other clinical trials.
Conclusions
Our findings propose a novel, although exclusive to the phase
I study of Lu et al. [3], potential candidate, CNOT1, for the
modulation of the response to the therapeutic vaccine and
do open a discussion on the need to consider the host, i.e. a
genome, as another variant likely to be evaluated when
designing an immune therapy study, or to be retrospectively
analysed once the study is completed. With this paper, being
aware of the limitations of our findings obtained on a low
number of patients and missing functional validation of the
genetic association because of lack of biological material,
we would like to recall the attention of other research
teams joining the workshop on DC-based vaccine clinical
trials group [1]. We would encourage them to create a
genetic network aimed at analysing the genomes of HIV
patients treated with DC-based immune therapy in order to
provide new insights on the role of the host genome in the
response to immune treatments.
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